Wanjing Chen

Wanjing Chen

Auto-generated profile, based on publicly available information

Wanjing Chen

Department of Health Management Center & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YLYing Liu
Ying Liu
PSPing Shuai
Ping Shuai
WCWanjing Chen
Wanjing Chen
YLYuping Liu
Yuping Liu
DLDongyu Li
Dongyu Li
Background and aim: The association between Helicobacter pylori (H. pylori) infection and metabolic syndrome (MetS) has been studied previously; however, the results remain controversial, which could be partly due to the different criteria used for defining MetS. We adopted five MetS criteria to provide better understanding of the association between H. pylori infection and MetS.Methods: Physical examination data of 100,708 subjects were obtained from January 2014 to December 2018. MetS was defined based on five criteria including: International Diabetes Federation (IDF), The Third Report of the National Cholesterol Education Program Expert Panel, Adult Treatment Panel III (ATP III), Joint Statement of International Multi-Societies (JIS), Chinese Diabetes Society (CDS), and the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 edition)(CDS DM). Multivariate logistic regression analysis was performed to elucidate the association between H. pylori infection and MetS and its components.Results: The prevalence of MetS defined assessed using IDF, ATP III, JIS, CDS and CDS DM criteria was 15.8%, 19.9%, 23.7%, 8.7% and 15.4%, respectively. In males, the prevalence of MetS assessed using the five criteria in H. pylori-positive group was higher than that in negative-group; however, in females, same results were obtained using the three international criteria. In males, the prevalence of all MetS components was found to be higher in the H. pylori-positive group than those in the negative group; however, in females, only the prevalence of dyslipidemia and waist circumferences exhibited significant differences. Multivariate logistic regression analysis revealed that H. pylori infection in males was positively correlated with MetS. Additionally, H. pylori infection was found to be positively correlated with the waist circumference in the general population, and with hypertension and hyperglycemia in males.Conclusions: H. pylori infection was found to be positively associated with MetS in males in China.

22 February 2022 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
GYGang Yu
Gang Yu
WCWanjing Chen
Wanjing Chen
XLXianghua Li
Xianghua Li
LYLiang Yu
Liang Yu
YXYan-Yan Xu
Yan-Yan Xu
YWYong Wang
Yong Wang
The association between collagen type I alpha (COL1A) and chemoresistance has been verified in cancers. However, the specific role of COL1A2 in gastric cancer (GC) cell resistance to apatinib, a highly selective small-molecule inhibitor of vascular endothelial growth factor receptor 2, has not been investigated before. The purpose of this study was to explore the potential factors associated with COL1A2 regulation on GC cell apatinib resistance in vitro. With the aid of the Oncomine database and integrated bioinformatics methods, we identified COL1A2 overexpression in GC and its prognostic value. Mechanistically, the COL1A2 promoter has a distinct H3K27ac modification site and that E1A binding protein p300 (EP300) and twist family bHLH transcription factor 1 (TWIST1) can bind to the COL1A2 promoter, which in turn transcriptionally activated COL1A2 expression. In addition, overexpression of COL1A2 significantly promoted resistance to apatinib in GC cells, but knockdown of EP300 or TWIST1 remarkably inhibited COL1A2 expression and promoted sensitivity of GC cells to apatinib. Our findings demonstrated that the combination of EP300 and TWIST1 has a synergistically regulatory effect on COL1A2 expression, thus contributing to apatinib resistance in GC cells.

20 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
WCWanjing Chen
Wanjing Chen
MMMengdi Ma
Mengdi Ma
ZZZhi Zhang
Zhi Zhang
QTQiong Teng
Qiong Teng
GYGang Yu
Gang Yu
YLYong-Xiang Li
Yong-Xiang Li
Chronic Helicobacter pylori infection drives gastric carcinogenesis by promoting epithelial transformation and reshaping the tumor immune microenvironment (TIME), yet the molecular mediators linking inflammation to tumor progression remain unclear. Cysteine- and glycine-rich protein 1 (CSRP1) is implicated in cancer, but its role in infection-driven immune reprogramming is unknown. We analyzed transcriptomic data from human gastric tissues and public databases to assess CSRP1 expression in relation to H. pylori infection, immune signatures, and clinical outcomes. In vitro and in vivo infection models were used to evaluate dynamic CSRP1 regulation. Functional assays measured tumor proliferation and invasion, while bioinformatic analyses and immunodetection assessed immune cell infiltration, cytokine signaling, PD-L1 expression, and macrophage polarization.CSRP1 was upregulated in gastric cancer, correlated with H. pylori infection, disease progression, and poor prognosis. Its knockdown reduced tumor proliferation and invasion. Mechanistically, CSRP1 activated IL-6/JAK2/STAT3 signaling, promoting epithelial–mesenchymal transition and pro-tumor inflammatory programs. High CSRP1 expression was associated with M2 macrophage enrichment, immunosuppressive cytokine networks, and increased PD-L1, suggesting engagement of immune checkpoint pathways and impaired anti-tumor immunity. These findings identify CSRP1 as a critical mediator linking H. pylori-driven chronic inflammation to EMT and immune microenvironment remodeling. By promoting STAT3-dependent tumor progression and immune evasion, CSRP1 represents a potential immunoregulatory biomarker and therapeutic target in infection-associated gastric cancer.